Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2012, Article ID 143927, 4 pages
http://dx.doi.org/10.1155/2012/143927
Case Report

Successful Treatment of Long-Term Severe Progressive Interstitial Pneumonia with Low-Dose Corticosteroid and Azathioprine in a Patient with Diffuse Systemic Sclerosis

First Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-Machi, Takatsuki, Osaka 569-8686, Japan

Received 3 July 2012; Accepted 5 September 2012

Academic Editors: H. Alexanderson, R. Aminov, J. V. Dunne, K. P. Makaritsis, P. E. Prete, and G. J. Tsay

Copyright © 2012 Takuya Kotani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Bérezné, D. Valeyre, B. Ranque, L. Guillevin, and L. Mouthon, “Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?” Annals of the New York Academy of Sciences, vol. 1110, pp. 271–284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Hamaguchi, M. Hasegawa, M. Fujimoto et al., “The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis,” British Journal of Dermatology, vol. 158, no. 3, pp. 487–495, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. K. B. Highland and R. M. Silver, “Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study,” Current Rheumatology Reports, vol. 7, no. 2, pp. 135–141, 2005. View at Google Scholar · View at Scopus
  4. D. P. Tashkin, R. Elashoff, P. J. Clements et al., “Cyclophosphamide versus placebo in scleroderma lung disease,” The New England Journal of Medicine, vol. 354, no. 25, pp. 2655–2666, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Khanna, D. E. Furst, P. J. Clements, D. P. Tashkin, and M. H. Eckman, “Oral cyclophosphamide for active scleroderma lung disease: a decision analysis,” Medical Decision Making, vol. 28, no. 6, pp. 926–937, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. K. Hoyles, R. W. Ellis, J. Wellsbury et al., “A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma,” Arthritis and Rheumatism, vol. 54, no. 12, pp. 3962–3970, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Raghu, W. J. Depaso, K. Cain et al., “Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial,” American Review of Respiratory Disease, vol. 144, no. 2, pp. 291–296, 1991. View at Google Scholar · View at Scopus
  8. V. V. Yurovsky, F. M. Wigley, R. A. Wise, and B. White, “Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis,” Human Immunology, vol. 48, no. 1-2, pp. 84–97, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Dheda, U. G. Lalloo, B. Cassim, and G. M. Mody, “Experience with azathioprine in systemic sclerosis associated with interstitial lung disease,” Clinical Rheumatology, vol. 23, no. 4, pp. 306–309, 2004. View at Google Scholar · View at Scopus